Key result
Dysferlinopathies are rare autosomal recessive neuromuscular diseases that can account for up to 30% of progressive recessive muscular dystrophies in the Middle East and Indian subcontinent.
Dysferlinopathies are a diverse group of autosomal recessive neuromuscular diseases that may benefit from innovative therapies targeting membrane repair and vesicle trafficking.
This is the authors' abstract. We don't add key points for this paper.
Dysferlinopathies encompass a large variety of neuromuscular diseases characterized by the absence of dysferlin in skeletal muscle and an autosomal recessive mode of inheritance. So far, three main phenotypes have been reported: Miyoshi myopathy (MM), limb girdle muscular dystrophy type 2B (LGMD 2B), and distal myopathy with anterior tibial onset (DMAT). A growing number of clinical variants have recently been described with a much wider range of symptoms and onset. Although rare, dysferlinopathies can account for up to 30% of progressive recessive muscular dystrophies in certain geographical areas, notably in the Middle East and the Indian subcontinent. Dysferlin is a large protein involved in membrane repair and vesicle trafficking and interacts probably with important immunological pathways. New insights in its pathophysiology may result in innovative therapies in the near future.
Answers are grounded in this paper and cite their sources.
May inform regional diagnostic strategies for muscular dystrophies; leaves open larger prevalence studies across diverse populations.
No takes yet. Share an insight, caveat, or question.
Urtizberea et al. (2008) conducted a review in Dysferlinopathies. Dysferlinopathies are rare autosomal recessive neuromuscular diseases that can account for up to 30% of progressive recessive muscular dystrophies in the Middle East and Indian subcontinent.
Synapse has enriched 10 related papers. Consider them for comparative context: